CSF levels of TNFα, TGFβ, IL1β, GM-CSF, tau, and Aβ in prospectively followed up MCI patients
| All patients | Patients with AD at follow up | Patients with MCI at follow up | Healthy controls | |
|---|---|---|---|---|
| (n=56) | (n=31) | (n=25) | (n=25) | |
| All data are presented as mean (SEM) (first row for each parameter) and median (interquartile range) (second row for each parameter) and are expressed in pg/ml for TNFα, ILβ, TGFβ, and Aβ, μ/ml for tau, and in ng/ml for GM-CSF. | ||||
| ***p<0.001 in comparison with controls. | ||||
| **p<0.01 in comparison with controls. | ||||
| TNFα | 0.4 (0.1)*** | 0.4 (0.1)*** | 0.4 (0.1)** | 0.2 (0.1) |
| 0.3 (0.5) | 0.3 (0.1) | 0.3 (0.4) | 0.0 (0.0) | |
| TGFβ | 124 (20)*** | 104 (6)*** | 149 (43)*** | 159 (10) |
| 99 (53) | 99 (46) | 94 (63) | 150 (61) | |
| IL1β | 0.04 (0.02) | 0.04 (0.02) | 0.05 (0.04) | 0.0 (0.0) |
| 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | |
| GM-CSF | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 18.0 (9.0) |
| 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (40.0) | |
| Tau | 600 (29)*** | 628 (29)*** | 564 (53)** | 314 (36) |
| 568 (313) | 588 (281) | 476 (382) | 299 (196) | |
| Aβ | 683 (42)** | 602 (43)*** | 784 (72) | 931 (55) |
| 557 (410) | 555 (167) | 698 (600) | 940 (219) | |